Country: South Africa
Language: English
Source: South African Health Products Regulatory Authority (SAHPRA)
Lennon
INDICATIONS [/za_1037.html#1] [/za_1037.html#1] [/za_1037.html#1] CONTRA-INDICATIONS [/za_1037.html#1] [/za_1037.html#1] DOSAGE [/za_1037.html#1] [/za_1037.html#1] SIDE-EFFECTS [/za_1037.html#1] [/za_1037.html#1] [/za_1037.html#1] PREGNANCY [/za_1037.html#1] [/za_1037.html#1] OVERDOSE [/za_1037.html#1] IDENTIFICATION [/za_1037.html#1] [/za_1037.html#1] PATIENT INFORMATION FENAMIN-250 CAPSULES FENAMIN-500 TABLETS FENAMIN SUSPENSION SCHEDULING STATUS: S3 S2 (see indications below) PROPRIETARY NAME (and dosage form): FENAMIN-250 CAPSULES FENAMIN-500 TABLETS FENAMIN SUSPENSION COMPOSITION Capsules containing 250 mg mefenamic acid Film coated tablets containing 500 mg mefenamic acid Suspension containing in each 5 mL 50 mg MEFENAMIC ACID PRESERVATIVES: Methylparaben 0,03% m/v Propylparaben 0,015% m/v Butylparaben 0,015% m/v PHARMACOLOGICAL CLASSIFICATION: A 2.7 Antipyretic and anti-inflammatory analgesics PHARMACOLOGICAL ACTION: Fenamin has anti-inflammatory activity and also antipyretic and analgesic properties. In analgesia it has a central as well as a peripheral action. Fenamin appears to owe those properties to its capacity to inhibit cyclo-oxygenase. Also it appears to antagonise certain effects of prostaglandins. INDICATIONS: S3: The relief of mild to moderate pain arising from rheumatic conditions, soft-tissue injuries, other painful musculoskeletal conditions and dysmenorrhoea. S2: Treatment of post traumatic conditions such as pain, swelling and inflammation for a maximum period of 5 days. CONTRA-INDICATIONS: Sensitivity to mefenamic acid and other non-steroidal anti-inflammatory agents, with prostaglandin synthetase inhibiting activity. The possibility of cross-sensitivity among non-steroidal anti-inflammatory agents exists. Fenamin is contra-indicated in patients with ulcerat Read the complete document